This content is restricted.
Brief
On 03/21/2025, the Food and Drug Administration (FDA) issued an update regarding FDA Roundup: March 21, 2025. The agency approved Fabhalta for treating adults with complement 3 glomerulopathy (C3G), a rare kidney disease. Additionally, FDA authorized marketing for the CORIS System, an automated endoscope cleaner, and updated instructions for use of Calyxo CVAC Aspiration Systems were issued as part of the medical device recall program pilot.
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested